Lihat Juga

• Angka Tahan Hidup Pasien Kanker Adenokarsinoma Paru yang Mendapat Terapi Target Epidermal Growth Factor Receptor – Tyrosin Kinase Inhibitor di Poli Paru RSUD Dr. Saiful Anwar Malang
  oleh: Bahar, Chaerani, et al.
  Terbitan: (2021)
• Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy
  oleh: Sahrun, Sahrun, et al.
  Terbitan: (2019)
• Profil Efikasi dan Toksisitas Terapi Target Baru Golongan Epidermal Factor Receptor-Tyrosine Kinase Inhibitor (EGFRTKi)Pada Pasien Kanker Paru Karsinoma Bukan Sel Kecil Non Skuamosa Dengan Mutasi EGFR Positif Dibandingkan Dengan Kemoradioterapi Pada EGFR Wild Type = Profile of Efficacy and Toxicity The New Targeted Therapy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKi) in Non Small Cell Lung Cancer Non-Squamous With Mutated EGFR Compared With Chemoradiotherapy In Wild Type
  oleh: Wiendo Syah Putra Yahya
  Terbitan: (2014)
• Peran quiescent lung cancer stem cell (CSC) dalam proses resistans terhadap agen epidermal growth factor receptortyrosine kinase inhibitor (EGFR-TKI) pada adenokarsinoma paru dengan mutasi EGFR positif = Role of quiescent lung cancer stem cells in epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR- TKI) resistance in EGFR-mutant lung adenocarcinoma
  oleh: Moulid Hidayat
  Terbitan: (2020)
• Profil efikasi dan toksisitas terapi target baru golongan Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKi) pada pasien kanker paru karsinoma bukan sel kecil non skuamosa dengan mutasi EGFR positif dibandingkan dengan kemoradioterapi pada EGFR Wild type = Profile of efficacy and toxicity the new targeted therapy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKi) in non small cell lung cancer non squamous with mutated EGFR compared with chemoradiotherapy in wild type
  Terbitan: (2014)